Charles River Laboratories International, Inc. (CRL)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 220.58 |
| Open | 222.75 |
| Bid | 90.18 x 1200 |
| Ask | 260.00 x 900 |
| Day's range | 220.23 - 226.43 |
| 52-week range | 203.37 - 460.21 |
| Volume | |
| Avg. volume | 549,348 |
| Market cap | 11.498B |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | 27.58 |
| EPS (TTM) | 8.20 |
| Earnings date | 02 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 327.64 |
- Business Wire
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
WILMINGTON, Mass. & GHENT, Belgium, June 23, 2022--Charles River and Ziphius Vaccines collaborate to deliver early-stage clinical supply of plasmid DNA for saRNA-based vaccine program.
- Zacks
Charles River (CRL) Prospers Internationally Amid FX Headwind
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
- Zacks
Charles River (CRL) to Create New Gene Therapy for Hemophilia A
Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.
© 2022 Yahoo. All rights reserved.
